Biology:Sulfate transporter
Generic protein structure example |
The sulfate transporter is a solute carrier family protein that in humans is encoded by the SLC26A2 gene.[1] SLC26A2 is also called the diastrophic dysplasia sulfate transporter (DTDST), and was first described by Hästbacka et al. in 1994.[1] A defect in sulfate activation described by Superti-Furga in achondrogenesis type 1B[2] was subsequently also found to be caused by genetic variants in the sulfate transporter gene.[3] This sulfate (SO42−) transporter also accepts chloride, hydroxyl ions (OH−), and oxalate as substrates.[4][5] SLC26A2 is expressed at high levels in developing and mature cartilage, as well as being expressed in lung, placenta, colon, kidney, pancreas and testis.[6][7]
Function
The diastrophic dysplasia sulfate transporter is a transmembrane glycoprotein implicated in the pathogenesis of several human chondrodysplasias. In chondrocytes, SLC26A2 functions to transport most of the cellular sulfate, which is critical for the sulfation of proteoglycans and normal cartilage formation.[8] In addition, studies have demonstrated that SLC26A2 influences chondrocyte proliferation, differentiation, and growth, suggesting that in the chondrocyte, SLC26A2 provides sulfate for both structural and regulatory proteins.[9]
Clinical significance
Deficiencies are associated with many forms of osteochondrodysplasia.[10][7] These include:
- achondrogenesis type 1B
- diastrophic dysplasia
- atelosteogenesis, type II
- recessive multiple epiphyseal dysplasia
Correlation between genotype and phenotype
Since its first description, over 30 mutations in the SLC26A2 gene have been described in the four recessively inherited chondrodysplasias listed above. Achondrogenesis 1B (ACG-1B) is the most severe form of these chondrodysplasias, resulting in skeletal underdevelopment and death preceding or shortly after birth.[11] Atelosteogenesis type II (AO-II) can be lethal in the neonatal period,[12] whereas diastrophic dysplasia (DTD) and autosomal recessive multiple epiphyseal dysplasia (EDM4/rMED) are considered to be the least severe forms.
When ten previously described SLC26A2 mutation were expressed in mammalian cells, a strong correlation was found between the amount of sulfate transport activity of the mutated protein and the severity of the phenotype in patients where these mutations have been identified.[13] For example, a mutation that results in a non-functional protein on both alleles was always found with the severe ACG-IB phenotype, but non-functional mutations on both alleles were never found with the less severe phenotypes, DTD and rMED. Mutations found in the moderately severe AO-II phenotype were always the result of a non-functioning mutation on one allele and a partial-functioning mutation on the opposite allele. In contrast, mutations described in the mildest form of the chondrodysplasia, rMED, result in proteins that retain at least some partial sulfate transport function on both alleles. This suggests that even a small amount of SLC26A2-mediated sulfate transport in chondrocytes can mitigate the clinical severity of the chondrodysplasia. However, a less predictable genotype/phenotype correlation has been found with a mutation described predominately in the Finnish population. This Finnish mutation is located in the splice site of the gene and results in low SLC26A2 mRNA levels.[14] Different levels of expression of the SLC26A2 protein is probably the cause of the variable phenotypes described with this mutation.
Functional significance of SLC26A2 in the colon and the kidney
Immunohistochemical analysis has localized SLC26A2 to the apical membrane of colon epithelial cells and kidney proximal tubule cells.[4][15]
Colon
Abundant SLC26A2 mRNA levels have been identified in the small and large intestine of mice, rats and humans. In the human colon, SLC26A2 is present in the upper third of the crypts, where it is directed toward the apical membrane.[16] The physiological role of SLC26A2 in the human colon remains to be determined, but it likely represent the sulfate/oxalate exchanger that has been characterized in colonic apical membrane vesicle preparations and possibly plays an important role in sulfate transport in this tissue.[17] In fact, impaired sulfation has been suggested to occur during the course of malignant transformation of colonic epithelial cells, and studies have shown that the growth rate of cancer cells was markedly enhanced when the transcription of SLC26A2 was suppressed.[18]
Kidney
The SLC26A2 protein has been localized to the brush border membrane of the rat kidney proximal tubule.[15] In that location, oxalate/SO42− exchange, or chloride/SO42− exchange by SLC26A2 might contribute to the critical process of sodium chloride reabsorption across the proximal tubular epithelium. Under one proposed model, an anion transporter exchanges intracellular oxalate for luminal chloride in parallel with the Na–SO4 cotransporter, resulting in net sodium chloride readsorption.[19] Under this model, a third transport process is required that functions as a method of recycling oxalate back into the cell, and recycling sulfate from the cell to the lumen. Previously, SLC26A6, another member of the same family of anion transporters as DTDST, was thought to provide the mechanism of oxalate- or formate-mediated chloride transport in this nephron segment; however, recent studies in Slc26a6-knockout mice have raised questions regarding its role in this transport process.[20] In contrast, the apical membrane location, and electrochemical properties of SLC26A2 would fit the requirement of an anion exchanger located on the apical membrane of the proximal tubule that would serve as a mechanism of transporting chloride in exchange for oxalate, and/or recycling oxalate in exchange for sulfate.
References
- ↑ 1.0 1.1 "The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping". Cell 78 (6): 1073–87. September 1994. doi:10.1016/0092-8674(94)90281-X. PMID 7923357.
- ↑ "A defect in the metabolic activation of sulfate in a patient with achondrogenesis type IB". American Journal of Human Genetics 55 (6): 1137–45. December 1994. PMID 7977372.
- ↑ "Achondrogenesis type IB is caused by mutations in the diastrophic dysplasia sulphate transporter gene". Nature Genetics 12 (1): 100–2. January 1996. doi:10.1038/ng0196-100. PMID 8528239.
- ↑ 4.0 4.1 "Regulated transport of sulfate and oxalate by SLC26A2/DTDST". American Journal of Physiology. Cell Physiology 298 (6): C1363-75. June 2010. doi:10.1152/ajpcell.00004.2010. PMID 20219950.
- ↑ "Solute carrier family 26 member a2 (Slc26a2) protein functions as an electroneutral SOFormula/OH-/Cl- exchanger regulated by extracellular Cl-". The Journal of Biological Chemistry 287 (7): 5122–32. February 2012. doi:10.1074/jbc.M111.297192. PMID 22190686.
- ↑ "SLC26A2 (diastrophic dysplasia sulfate transporter) is expressed in developing and mature cartilage but also in other tissues and cell types". The Journal of Histochemistry and Cytochemistry 49 (8): 973–82. August 2001. doi:10.1177/002215540104900805. PMID 11457925.
- ↑ 7.0 7.1 "A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype". Human Molecular Genetics 14 (6): 859–71. March 2005. doi:10.1093/hmg/ddi079. PMID 15703192.
- ↑ "Entrez Gene: SLC26A2". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1836.
- ↑ "Multiple roles of the SO4(2-)/Cl-/OH- exchanger protein Slc26a2 in chondrocyte functions". The Journal of Biological Chemistry 289 (4): 1993–2001. January 2014. doi:10.1074/jbc.M113.503466. PMID 24302720.
- ↑ Superti-Furga A, Hästbacka J, Rossi A, van der Harten JJ, Wilcox WR, Cohn DH, Rimoin DL, Steinmann B, Lander ES, Gitzelmann R. A family of chondrodysplasias caused by mutations in the diastrophic dysplasia sulfate transporter gene and associated with impaired sulfation of proteoglycans. Ann N Y Acad Sci. 1996 Jun 8;785:195-201. doi: 10.1111/j.1749-6632.1996.tb56259.x. PMID: 8702127.
- ↑ "Achondrogenesis type IB is caused by mutations in the diastrophic dysplasia sulphate transporter gene". Nature Genetics 12 (1): 100–2. January 1996. doi:10.1038/ng0196-100. PMID 8528239.
- ↑ "Atelosteogenesis type II is caused by mutations in the diastrophic dysplasia sulfate-transporter gene (DTDST): evidence for a phenotypic series involving three chondrodysplasias". American Journal of Human Genetics 58 (2): 255–62. February 1996. PMID 8571951.
- ↑ "Functional expression and cellular distribution of diastrophic dysplasia sulfate transporter (DTDST) gene mutations in HEK cells". Human Molecular Genetics 13 (19): 2165–71. October 2004. doi:10.1093/hmg/ddh242. PMID 15294877.
- ↑ "Identification of the Finnish founder mutation for diastrophic dysplasia (DTD)". European Journal of Human Genetics 7 (6): 664–70. September 1999. doi:10.1038/sj.ejhg.5200361. PMID 10482955.
- ↑ 15.0 15.1 "Protein localization of SLC26A2 (DTDST) in rat kidney". Histochemistry and Cell Biology 133 (5): 541–7. May 2010. doi:10.1007/s00418-010-0694-x. PMID 20369363.
- ↑ "The congenital chloride diarrhea gene is expressed in seminal vesicle, sweat gland, inflammatory colon epithelium, and in some dysplastic colon cells". Histochemistry and Cell Biology 113 (4): 279–86. April 2000. doi:10.1007/s004180000131. PMID 10857479.
- ↑ "Evidence for the existence of a distinct SO(4)(--)-OH(-) exchange mechanism in the human proximal colonic apical membrane vesicles and its possible role in chloride transport". Experimental Biology and Medicine 226 (10): 912–8. November 2001. doi:10.1177/153537020122601006. PMID 11682697.
- ↑ "Epigenetic silencing of the sulfate transporter gene DTDST induces sialyl Lewisx expression and accelerates proliferation of colon cancer cells". Cancer Research 70 (10): 4064–73. May 2010. doi:10.1158/0008-5472.CAN-09-2383. PMID 20460514.
- ↑ "Pathways for oxalate transport in rabbit renal microvillus membrane vesicles". The Journal of Biological Chemistry 271 (26): 15491–7. June 1996. doi:10.1074/jbc.271.26.15491. PMID 8663096.
- ↑ "Characterization of renal NaCl and oxalate transport in Slc26a6 -/- mice". American Journal of Physiology. Renal Physiology 316 (1): F128–F133. January 2019. doi:10.1152/ajprenal.00309.2018. PMID 30427220.
Further reading
- "Proteoglycan sulfation in cartilage and cell cultures from patients with sulfate transporter chondrodysplasias: relationship to clinical severity and indications on the role of intracellular sulfate production". Matrix Biology 17 (5): 361–9. October 1998. doi:10.1016/S0945-053X(98)90088-9. PMID 9822202.
- "Mutations in the known genes are not the major cause of MED; distinctive phenotypic entities among patients with no identified mutations". European Journal of Human Genetics 13 (3): 292–301. March 2005. doi:10.1038/sj.ejhg.5201314. PMID 15523498.
- "A novel mutation in the sulfate transporter gene SLC26A2 (DTDST) specific to the Finnish population causes de la Chapelle dysplasia". Journal of Medical Genetics 45 (12): 827–31. December 2008. doi:10.1136/jmg.2007.057158. PMID 18708426.
- "Functional characterization of three novel tissue-specific anion exchangers SLC26A7, -A8, and -A9". The Journal of Biological Chemistry 277 (16): 14246–54. April 2002. doi:10.1074/jbc.M111802200. PMID 11834742.
- "Positive association of SLC26A2 gene polymorphisms with susceptibility to systemic-onset juvenile idiopathic arthritis". Arthritis and Rheumatism 56 (4): 1286–91. April 2007. doi:10.1002/art.22444. PMID 17393463.
- "Identification of sequence polymorphisms in two sulfation-related genes, PAPSS2 and SLC26A2, and an association analysis with knee osteoarthritis". Journal of Human Genetics 46 (9): 538–43. 2001. doi:10.1007/s100380170036. PMID 11558903.
- "Homozygosity for a novel DTDST mutation in a child with a 'broad bone-platyspondylic' variant of diastrophic dysplasia". Clinical Genetics 56 (1): 71–6. July 1999. doi:10.1034/j.1399-0004.1999.560110.x. PMID 10466420.
- "Physiological roles and regulation of mammalian sulfate transporters". Physiological Reviews 81 (4): 1499–533. October 2001. doi:10.1152/physrev.2001.81.4.1499. PMID 11581495.
- "In vivo contribution of amino acid sulfur to cartilage proteoglycan sulfation". The Biochemical Journal 398 (3): 509–14. September 2006. doi:10.1042/BJ20060566. PMID 16719839.
- "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks". Cell 127 (3): 635–48. November 2006. doi:10.1016/j.cell.2006.09.026. PMID 17081983.
- "Functional analysis of diastrophic dysplasia sulfate transporter. Its involvement in growth regulation of chondrocytes mediated by sulfated proteoglycans". The Journal of Biological Chemistry 273 (20): 12307–15. May 1998. doi:10.1074/jbc.273.20.12307. PMID 9575183.
- "Autosomal recessive multiple epiphyseal dysplasia with homozygosity for C653S in the DTDST gene: double-layer patella as a reliable sign". American Journal of Medical Genetics. Part A 122A (3): 187–92. October 2003. doi:10.1002/ajmg.a.20282. PMID 12966518.
- "Mapping of five new putative anion transporter genes in human and characterization of SLC26A6, a candidate gene for pancreatic anion exchanger". Genomics 70 (1): 102–12. November 2000. doi:10.1006/geno.2000.6355. PMID 11087667.
- "Requirements for sulfate transport and the diastrophic dysplasia sulfate transporter in fibronectin matrix assembly". The Journal of Cell Biology 179 (5): 999–1009. December 2007. doi:10.1083/jcb.200707150. PMID 18056413.
- "In vitro proteoglycan sulfation derived from sulfhydryl compounds in sulfate transporter chondrodysplasias". Pediatric Pathology & Molecular Medicine 22 (4): 311–21. 2003. doi:10.1080/15227950307720. PMID 14692227.
- "Does genotype predict development of the spinal deformity in patients with diastrophic dysplasia?". European Spine Journal 11 (4): 327–31. August 2002. doi:10.1007/s00586-002-0413-y. PMID 12193993.
- "SLC26A2 (diastrophic dysplasia sulfate transporter) is expressed in developing and mature cartilage but also in other tissues and cell types". The Journal of Histochemistry and Cytochemistry 49 (8): 973–82. August 2001. doi:10.1177/002215540104900805. PMID 11457925.
- "The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis". Bone 45 (2): 289–94. August 2009. doi:10.1016/j.bone.2009.03.676. PMID 19371798.
- "SLC26A2-Related Multiple Epiphyseal Dysplasia". Multiple Epiphyseal Dysplasia, Recessive. University of Washington, Seattle. 2014-01-23. NBK1306. https://www.ncbi.nlm.nih.gov/books/NBK1306/. In Adam, M. P.; Feldman, J.; Mirzaa, G. M.; Pagon, R. A.; Wallace, S. E.; Bean LJH; Gripp, K. W.; Amemiya, A. (2002). GeneReviews [Internet]. Seattle WA: University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/n/gene/TOC/.
- "SLC26A2-Related Atelosteogenesis". Atelosteogenesis Type 2. University of Washington, Seattle. 2014-01-23. NBK1317. https://www.ncbi.nlm.nih.gov/books/NBK1317/. In GeneReviews
- Diastrophic Dysplasia. University of Washington, Seattle. 2013-07-18. NBK1350. https://www.ncbi.nlm.nih.gov/books/NBK1350/. In GeneReviews
External links
- SLC26A2+protein,+human at the US National Library of Medicine Medical Subject Headings (MeSH)
- Online Mendelian Inheritance in Man (OMIM) Epiphyseal Dysplasia, Multiple, 1; EDM1 -132400
- Online Mendelian Inheritance in Man (OMIM) Pendred Syndrome; PDS -274600
- Online Mendelian Inheritance in Man (OMIM) Epiphyseal Dysplasia, Multiple, 4; EDM4 -226900
- Online Mendelian Inheritance in Man (OMIM) Solute Carrier Family 26 (Sulfate Transporter), Member 2; SLC26A2 -606718
- Online Mendelian Inheritance in Man (OMIM) Atelosteogenesis, Type II; AOII -256050
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Original source: https://en.wikipedia.org/wiki/Sulfate transporter.
Read more |